Virtual Library
Start Your Search
Nazim Serdar Turhal
Author of
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey (ID 14012)
16:45 - 18:00 | Author(s): Nazim Serdar Turhal
- Abstract
Background
ALK mutation is observed in 4% of patients diagnosed with NSCLC. The present study aimed to evaluate the efficacy of crizotinib, an ALK inhibitor, and clinical characteristics of ALK-positive NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
In this multicenter, retrospective study, data of ALK-positive advanced stage NSCLC patients who received crizotinib were retrieved from hospital records.
4c3880bb027f159e801041b1021e88e8 Result
Data of 353 ALK-positive metastatic NSCLC patients receiving crizotinib in any treatment line were analyzed. The mean age of the patients was 53.2±12.6 years [median, 53 years (21-85 years)] and 193 (54.7%) patients were male. Age at diagnosis was significantly higher in males than in females (54.8±11.8 years and 51.3±13.2 years, respectively; p=0.044). The rate of patients who never smoked was 50.1%. The most common histological subtype was adenocarcinoma (96%). The frequency of brain metastasis at the time of diagnosis was 23.4%. The most common initial symptoms were cough (56%) and dyspnea (53%). Initial ECOG score was 0 or 1 in 80% of the patients. Crizotinib had been used in 37% of the patients in the 1st-line treatment, in 45% of the patients in the 2nd-line treatment, and in 18% of the patients in the ≥3rd-line treatment.
Table 1. Response rates of the patients
Treatment line
Overall
N (%)1
N (%)2
N (%)3
N (%)Other
N (%)Complete response
28 (7.9)
9 (7.3)
14 (8.9)
4 (9.8)
1 (5.6)
Partial response
217 (61.5)
78 (62.9)
103 (65.2)
25 (61.0)
10 (55.6)
Stable disease
50 (14.2)
18 (14.5)
21 (13.3)
7 (17.1)
4 (22.2)
Progressive disease
67 (13.3)
19 (15.3)
20 (12.7)
5 (12.2)
3 (16.7)
Undefined
11 (3.1)
ORR
245 (69.4)
87 (70.2)
117 (74.1)
29 (70.8)
11 (61.2)
DCR
295 (83.6)
105 (84.7)
138 (87.4)
36 (87.1)
7 (83.4)
Undefined
11 (3.1)
ORR was 69.4% and DCR was 83.6% (Table 1). ORR and DCR in the patients received crizotinib were 70.2% and 84.7% in the 1st-line treatment, respectively and were 74.1% and 87.4% in the 2nd-line treatment, respectively. The frequency of brain metastasis was 40.2% at 12 months. Of these patients, the median PFS and OS were 11.3 and 28.0 months, respectively.
The most common side effects were fatigue, visual disturbances, nausea, abdominal discomfort, and pretibial edema.
8eea62084ca7e541d918e823422bd82e Conclusion
Clinical characteristics of ALK-positive patients and crizotinib efficacy are consistent with studies. Response rates and survival outcomes are similar regardless of treatment lines. Crizotinib is safely used in these patients.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 981)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.15-27 - Initial Response to First Line Treatment is the Best Predictor of the Patient Survival in Advanced NSCLC (ID 12438)
12:00 - 13:30 | Presenting Author(s): Nazim Serdar Turhal
- Abstract
Background
Although most of the NSCLC patients are treated according to the standart guidelines, the patients who present in routine clinical practice usually have inferior performance status, in comparison to the patients registered in the clinical trials. Also in comparison, the frequency and thoroughness of the tests and procedures the clinical trial patients subjected are more intense as well. The oncologist practising in community needs simpler ways and means to assess patients' disease course to make timely and reliable judgement on their management.
a9ded1e5ce5d75814730bb4caaf49419 Method
We searched among 5130 patients treated in our clinic since 2006 to find 678 lung cancer patients of all stages and pathology. Of these, 171 advanced stage NSCLC patients that were treated primarily under our supervision are selected for the calculations. The other histologies and the patients seen once or twice for a second opinion are excluded. The common patients characteristics including age, gender, stage, date of diagnosis, the date of progression, the site and the number of metastasis etc. are all recorded.
4c3880bb027f159e801041b1021e88e8 Result
The median age of the patients were 62, 23% were female, the median overall survival was 18 months. The majority did not receive any targeted immunotherapy because either it did not exist back then or they had access problems in more recent times. We did then univariate/moltivariate analysis of survival according to the age, gender, site of metastasis, platin vs non-platin based treatment and response to first line of chemotherapy. Of these, only the response to first line of therapy appeared as a statitically significant variable, 23 vs 14 months with p=0.0001. In over 90% of the patients, the radiological findings were in line with clinical picture.
8eea62084ca7e541d918e823422bd82e Conclusion
Although more complex and costly measures exist to predict the overall survival of the NSCLC patients, in our experience the clinical responsiveness to first line of chemotherapy most precisely predicted the overall survival. This simple measure may help the healthcare profesionals to understand the disease course of the patients and manage their needs in more proper fashion.
6f8b794f3246b0c1e1780bb4d4d5dc53